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Summary
Background: The development of second malignant neoplasms (SMNs) in patients receiving chemotherapy
and radiation therapy for primary cancers is one of the limitations to the quality and length of
survival. The present study was undertaken to examine various characteristics of children who
developed SMNs following successful therapy for primary leukemia or Hodgkin’s disease (HD).
Material/Methods: A total of 3252 children with various forms of leukemia and 849 children with HD treated
between, 1970–1997 at 7 pediatric centers of the Polish Pediatric Hematology/Oncology
Group and subsequently followed-up entered the study. A second malignancy was diagnosed
in 36 of these children.
Results: Of the 3252 patients diagnosed as having acute leukemia during this period, 16 developed
SMNs (estimated frequency 0.49%). SMNs developed in 20 of the 849 children treated for HD
(2.36%). The most frequent SMNs were soft tissue sarcoma and thyroid carcinomas, mainly fol-
lowing Hodgkin’s disease. Other tumors occurred at about the same frequencies in both groups.
The interval from the end of initial treatment to diagnosis of an SMN ranged from 2 years 7
months to 17 years 6 months, with a median of 7 yrs 4 mo. for acute lymphoblastic leukemia
(ALL) patients and 10 years for children with HD. The estimated accumulated risk of SMN fol-
lowing acute leukemia is 0.95% at 15 years and, for HD, 5.1% at 20 yrs and 7% at 25 yrs.
Conclusions: Children who have been successfully treated for one cancer have a higher than expected inci-
dence of additional tumors.
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BACKGROUND
Major advances in the treatment of childhood leukemia
and other neoplasms have led to a significant improve-
ment in survival. However, combined modality therapy,
involving both chemotherapy and radiation therapy,
also results in late side effects. One of the limitations to
the quality and length of survival has been the develop-
ment of second malignant neoplasms. Both radiation
and chemotherapy have potential mutagenic and car-
cinogenic effects. A single radiation exposure is suffi-
cient to increase the risk of cancer many years later.
Many forms of chemotherapy have an effect on nucleic
acid metabolism and are therefore potentially muta-
genic. Alkylating agents are most frequently implicated
in these chemotherapy-induced tumors [1–5].
The present study was undertaken to examine various
characteristics of children who developed second malig-
nant neoplasms (SMNs) following successful therapy for
primary leukemia or Hodgkin’s disease at 7 centers of
the Polish Pediatric Leukemia/Lymphoma Group.
MATERIAL AND METHODS
A total of 3252 children with various forms of leukemia
and 849 children treated for Hodgkin’s disease entered
the study. They had been treated between, 1970–1997
in 7 pediatric hematology/oncology centers of the Polish
Pediatric Leukemia/Lymphoma Group and then a fol-
low-up of each patient was performed at these centers.
The information collected on each patient included sex,
date of birth, family history of neoplasms and immune
deficiencies, parents’ occupations, and exposure to
mutagenic agents. The description of the first malignant
disease consisted of the date of diagnosis, histologic or
cytologic diagnoses, clinical and hematologic features at
diagnosis, and the type of chemotherapy and radiation
therapy.
Details regarding second malignant tumors concerned
the date of the second diagnosis, histologic examination,
site, therapy and outcome. The estimated cumulative
risk of SMNs was calculated according to the Kaplan-
Meyer method. The at-risk time for a second malignan-
cy began at the start of the first treatment with chemo-
therapy and ended on the date of diagnosis of the se-
cond neoplasm, the date of death, or the date of the
most recent medical follow-up examination, whichever
came first.
RESULTS
In the cohort of 4100 children with leukemia or
Hodgkin’s disease treated at our institutions, a second
malignant tumor was diagnosed in 36 children. Primary
malignancies in our patients had been diagnosed
between, 1970 and, 1991. Of the total of 3252 children
diagnosed with acute lymphoblastic leukemia (ALL)
during this period, 16 developed SMNs. Their primary
malignancy had been diagnosed at ages ranging from 2
years 8 months to 8 years 10 months (median 5.3 years).
SMNs developed in 20 of the 849 children treated for
Hodgkin’s disease (HD), first diagnosed at ages ranging
from 5 years to 11 years 4 months (median 7.19 years)
The second malignant tumors were disclosed in our
patients between, 1977 and, 1997. Table 1 summarizes
some of the clinical data of the 36 children who devel-
oped second tumors. A familial history of malignancies
was not determined in any child with primary ALL. In 1
HD case, we obtained information concerning neoplas-
tic diseases in family members which may suggest can-
cer susceptibility.
The distribution of second neoplasms in patients, divid-
ed into groups on the basis of type of the primary
malignancy, is presented in the Table 2. The most fre-
quent tumor was soft-tissue sarcoma, mainly following
HD. Non-Hodgkin’s lymphoma and neoplasms of the
liver and central nervous system were observed in chil-
dren treated for primary ALL.
The interval from the end of initial treatment to diagno-
sis of a second malignant neoplasm ranged from 2 yrs 7
mo. to 17 yrs 6 mo. with a median of 7 yrs 4 mo. for
ALL patients and from 1 yr 11 mo. to 23 yrs. 7 mo. with
a median of 10 yrs for HD patients.
Almost all patients had initially received both chemo-
therapy and radiation therapy. ALL children were treat-
ed according to protocols used at the time of diagnosis, i.
e. BFM 81 or BFM 87, in all but four patients. Cranial
irradiation was performed in all but one of these patients.
In that child, astrocytoma developed as a secondary neo-
plasm. Chemotherapy of HD consisted of 6–8 cycles of
the MVPP protocol in each case, 3 children receiving, in
addition, courses of the B DOPA regimen protocol. All
HD patients also received local radiation therapy.
Fourteen of our patients died of second neoplasms (8
ALL, 6 HD) and 20 children (63.8%) are still in remis-
sion (7 ALL, 13 HD). Information on 2 patients was not
available.
The estimated cumulative risk for second malignant neo-
plasm in children with primary ALL was 0.05% at 5
years, 0.5% at 10 years, and 0.95% at 15 years (Figure 1).
For patients with Hodgkin’s disease the cumulative risk
in our cohort was 0.02% at 5 years, 1% at 10 years, 3.5%
at 15 years, 5% at 20 years, and 7% at 25 years (Figure 2).
DISCUSSION
It is now apparent that childhood cancer patients who
have been successfully treated for one cancer have a
higher than expected incidence of additional tumors
[6]. The estimated risk of a child developing cancer in
the first 15 years of life in the general Polish population
is approximately 0.16% [7]. Thus, the cumulative risk
for second malignant neoplasm following ALL in our
study was 6 times higher than in the general population
and 22 times higher for patients with HD.
Despite recent interest in second tumors, little is know
about risk factors, in particular the influence of treat-
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ment of the first primary neoplasm on the development
of a second. Two cause are most likely: the induction of
second tumors by treatment with mutagenic and car-
cinogenic agents, and the survival of a group of patients
with increased susceptibility to cancer. Whether treat-
ment is a direct or indirect cause of SMN or whether
the prolonged survival induced by such treatment
allows for the development of SMN in a genetically sus-
ceptible subject cannot be answered with certainty. Most
studies implicate X-radiation as the causative agent, but
there is now evidence that patients treated with
chemotherapy, especially with alkylating agents, also
have an increased risk of second primary tumors, and
those treated with both X-ray and chemotherapy have
the highest incidence of all [1,3,5,8,9].
SMN incidence, or the cumulative risk of SMN, in
patients previously treated for primary cancer differs in
the groups studied [1–5,10–21]. Since different cure
rates have to be considered throughout the years,
1959–1990, the incidence of second malignancies cannot
be directly related to the total number of patients, but
only to the percentage of long-term survivors, which was
less than 20% for patients with leukemia in the years,
1950–1970 and more than 60% in, 1980–1990 [22].
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CR
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D
D
D
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NHL
Hepatoblastoma
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HD
Astrocytoma
Synovioma malignum
Ca gl. thyroid.
Osteosarcoma
NHL
Melanoma malignum
Osteosarcoma
Renal cell ca
Astrocytoma
B-NHL
Hepatoma
Astrocytoma
NHL
Fibrosarcoma
Fibrosarc.+ Leiomyosarc.
Chondrosarcoma
Bronchoalveoral ca
Ca gl. thyroid.
Ewing sa.
Adenoma foll. gl. thyroid.
Hepatocarcinoma
Fibrosarcoma
Neurofibroma
NHL
Astrocytoma
Tu cerebri- PNET
NHL
RMS
Ca hepatis
Ca basocell.
Ca gl. thyroid.
Ca gl. thyroid.
Table 1. Characteristics of patients with second malignant neoplasms.
SMN – second malignant neoplasm; ALL – acute lymphoblastic leukemia;
HD – Hodgkin's disease
SMN (total)
Primary tumors
ALL (16) HD (20)
Soft tissue sarc. (5) 
NHL (6)
Liver neopl. (5)
Brain tu. (6)
Bone tu. (4)
Thyroid tu. (5)
HD (1)
Lung ca (1)
Other (3)
1
3
3
3
2
1
1
–
2
4
3
2
3
2
4
–
1
1
Table 2. Distribution of first and second malignant neoplasms.
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Few studies have attempted to describe the overall risk
of a second neoplasm among children with ALL. In the
4373 children with leukemia studied by the Late Effect
Study Group, only 5 (0.11%) developed SMN [10]. Pui
et al. [3] studied the risk of the development of AML in
733 children with a primary diagnosis of ALL and treat-
ed with intensive chemotherapy. The cumulative risk
was 1.6% at 3 years, and 4.7% at 6 years. In another
study, 3% of 95 ALL patients developed SMN [11].
Neglia et al. [12] found an SMN incidence of 0.44% in
9720 children who had been diagnosed with ALL. In
more recent studies from Nordic countries [13], the
cumulative risk of SMN in patients treated for primary
leukemia, based on a cohort of 981 children, was 2.9%
at 20 years. The Italian Group [14] reported a study
within a cohort that included 1806 patients with
leukemia and they found that the cumulative risk was
0.1% at 5 years 2.6% at 10 years, and 4.5% at 15 years. A
cohort of 8831 children diagnosed with ALL and
enrolled in Children’s Cancer Group therapeutic proto-
cols between, 1983 and, 1995 were observed to deter-
mine the incidence of second neoplasms and associated
risk factors. Sixty-three patients developed second neo-
plasms. The cumulative incidence of any second neo-
plasm was 1.18% at 10 years, representing a 7.2-fold
increased risk compared with the general population
[15]. The BFM Group presented a study of 5006 chil-
dren with B-precursor or T-ALL who were enrolled in 5
ALL-BFM multicenter trials. A total of 52 second malig-
nancies were documented in these group [16].
Compared with the expected numbers estimated from
incidence rates, this represented a 14-fold increase for
all cancers, and the overall cumulative risk of SMN at 15
years was 3.3%.
These figures are higher than the results estimated in
our study, i.e. 0.05%, 0.5%, and 0.90%, respectively. The
number of children with ALL at follow-up (3252) in our
study was, however, comparable to that in other studies.
The frequency of SMN has been extensively investigated
in patients successfully treated for Hodgkin’s disease
(HD). Tester et al. [4] reported actuarial estimates of the
risk of AML and secondary solid tumors for patients
treated for HD. The risk of developing AML 10 years
after diagnosis was 6±4.5% among patients treated with
MOPP + radiation therapy. The actuarial risk of devel-
oping a solid SMN was 7±2.6% among those treated with
radiation therapy only, and 7±4% among those treated
with initial combined-modality therapy. In another
group of 441 patients with HD treated with a MOPP regi-
men, SMN developed in 2.27%, and the actuarial risk at
15 years was 3.5% [23]. The Late Effects Study Group
reported on 1380 children with HD and 88 SMN were
diagnosed (expected: 4.4). The estimated actuarial inci-
dence of SMN 15 years after diagnosis of HD was 7%
[17]. This is in good agreement with results presented by
Beaty [18]. The cumulative risk estimated in Nordic
countries was 1.9% at 10 years, 6.9% at 20 years, and 18%
at 30 years [19]. Higher risks were estimated in, 1939
Dutch patients, with 20% at 20 years [20], and in a cohort
reported by Green et al. [24], with 26.27±6.75% at 30
years after diagnosis. Lower, however, cumulative risk
was reported in a cohort of Italian patients, with 0.8% at
5 years, 1.6% at 10 years, and 4.1% at 15 years (14).
The risk of second cancers estimated in our cohort of
children with HD 15 years after diagnosis (3.5%) is close
to the last value and lower than that presented in most
other papers. Schellong et al. [21] recently reported on
a group of 667 children with HD and estimated the risk
even smaller than in our study (1.1% at 15 years).
The median interval from initial therapy to the develop-
ment of secondary acute leukemia was reported to be
from 23 months to 110 months [14,17], i. e. from less
than 2 years to almost 10 years. In most studies, howev-
er, the median time between the beginning of treatment
of the primary tumor and the diagnosis of the second
acute leukemia was 36 months [3], 48 months [8], 57
months [25], 60 months [26,27], and 94 months [28]. In
all studies, the latent period for second leukemia ranged
from 11 months to 17 years. In patients treated previ-
ously for HD, the latent period seemed to be similar to
that observed in patients with primary leukemia, i. e.
about 6 years in most studies [2,29] and 4.2 years in the
cohort reported by Lavay [1].
SMN in our patients developed after a latent interval
ranging from 31 months to 17 years 4 mo. (median: 7
years
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Figure 1. Cumulative risk for SMN in children with acute lymphoblastic
leukemia.
Figure 2. Cumulative risk for SMN in children with Hodgkin
disease.
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years 4 mo.) for ALL patients and from 13 months to 23
years 7 months for HD patients. This time between the
diagnosis of primary cancer and a second neoplasm is in
good agreement with most other reports. In patients
treated for lung cancer, SMN also developed after a
mean time of 50.6 months [30]. In another group of
patients with different primary neoplasms, SMN was
observed after a mean time of 5 years, but the latent
period was longer (10 years) for patients whose SMN
developed after radiotherapy [9]. Whitlock et al. [5] stat-
ed that the latency period for etoposide-related or teni-
poside-related ANLL is significantly shorter than that
for ANLL occurring secondary to alkylating agents. The
mean interval from exposure to an epipodophyllotoxin
to the onset of leukemia is 33 months, in contrast to a
mean interval of 58 to 73 months for alkylating agent-
associated or radiation-associated leukemia.
The incidence of SMN is time dependent and the medi-
an follow-up period of patients seems to play an impor-
tant role [2]. The risk increases significantly between
5–10 years from the first tumor diagnosis and gradually
reduces a level of the expected outcome thereafter
[1,5,6,31].
The diagnosis of a second malignancy in children shortly
after the diagnosis of a primary cancer might indicate
that cases of relapse or metastases were concealed among
the group designated as second primaries [6]. Currently,
a proper diagnosis is much more likely using immuno-
logic and cytogenetic methods and new imaging tech-
niques. The occurrence of a second cancer in a child
may depend on factors other than previous therapy: it
may also be a result of a combination of age, genetics
and, possibly, therapy (2, 12). Genetic predisposition is
thought to play a special role in the development of
SMN. Well-defined cytogenetic abnormalities have been
reported for secondary leukemias [5,8,25,28–34).
The clinical outcome of treatment in our patients with
SMN seems to be better than in previous reports [3]. At
least 50% of the 36 children in our study are still in a
second complete remission with the shortest follow-up
period of 2 years.
As survival continues to improve, second cancers and
other late effects of therapy will play an increasingly
prominent part in the long-term care of children with
cancer. It is not certain, however, whether the intensity
of the treatment presently being administered is needed
to achieve cure. An optimal balance between the risks
and benefits of treatment must be applied.
CONCLUSIONS
Childhood patients who have been successfully treated
for one cancer have a higher than expected incidence of
additional tumors. The cumulative risk for second malig-
nant neoplasm following ALL in our study was 6 times
higher than in the general population and 22 times
higher for patients with HD. The SMNs in our patients
developed after a median latency interval of 7 years 4
mo. for ALL patients and 10 years for HD patients.
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